Janssen and Bristol-Myers Squibb Company in collaboration over immuno-oncology in lung cancer





Janssen Biotech, Inc announced it has entered into a clinical study collaboration agreement with Bristol-Myers Squibb Company to evaluate the combination of two immuno-oncology compounds in patients with non-small cell lung cancer (NSCLC).
 
The Phase 2 clinical trial will evaluate the tolerability and clinical activity of the combination of Janssen’s investigational immunotherapy JNJ-64041757 and Bristol-Myer Squibb’s PD-1 immune checkpoint inhibitor, OPDIVO® (nivolumab), in NSCLC patients.
JNJ-64041757 is an antigen-presentation therapeutic, based on Live Attenuated Double-Deleted (LADD) Listeria monocytogenes strains engineered to induce an immune response against NSCLC tumors.  Janssen licensed JNJ-64041757 (previously referred to as ADU-214) and another compound, JNJ-64041809 (previously referred to as ADU-741), from Aduro Biotech, Inc., in 2014. Both are currently in Phase 1 clinical development: JNJ-64041757 in lung cancer and JNJ-64041809 in prostate cancer.   OPDIVO is indicated for the treatment of patients with NSCLC with progression on or after platinum-based chemotherapy.
“Cancer immunotherapy is a key aspect of our emerging lung cancer portfolio,” said Matthew Lorenzi, Ph.D., Vice President, Lung Cancer, Janssen Research & Development, LLC.  “This collaboration will help extend the clinical development of JNJ-64041757 while allowing us to gather data on the immune response triggered by the combination of these two innovative approaches.”
 
The study will be conducted by Janssen.  Information, including anticipated study start, is expected to be posted on www.clinicaltrials.gov later this year. Additional details of the collaboration were not disclosed.
 
About the Janssen Pharmaceutical Companies
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com
Media Inquiries:
Kellie McLaughlin
Phone: 1-908-927-7477
Mobile: 1-609-468-8356
Investor Relations:
Lesley Fishman
Phone: 1-732-524-3922